SPARC Q3 FY26 results: Revenue declines, loss widens with exceptional charge

Going ConcernExceptional ItemRevenue DeclinePat NegativeResults View source PDF Explain this filing

SPARC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹139.20

prior close

₹140.96

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+2.6%-3.5% vs market

Pharmaceuticals peers, median of 159sector+1.8%-2.7% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 2.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.2

15m

-0.3

30m

-2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9+2.6-3.5+1.8-2.7

Next day

+1.2+3.6-2.4+2.4-1.2

-1.7+3.1-4.8+2.0-3.8

-3.1+2.6-5.6+1.3-4.4

-5.2+1.1-6.2+0.7-5.9

-4.0+0.3-4.3+0.0-4.0

-5.1+1.6-6.7+0.8-5.8

15d

-9.0-3.9-5.1-4.3-4.7

-13.1-8.1-5.0-5.2-7.9

+4.7-3.1+7.8-3.0+7.6

+21.3+9.2+12.2+4.6+16.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SPARC Q3 FY26 standalone revenue fell to Rs. 845 lakhs from Rs. 1,491 lakhs year-ago. 9-month revenue declined to Rs. 2,595 lakhs from Rs. 4,458 lakhs. Net loss was Rs. 8,057 lakhs for Q3 and Rs. 20,857 lakhs for 9M, including a Rs. 1,236 lakh exceptional charge for new Labour Codes. Going concern support from promoter noted. US FDA granted a Priority Review Voucher for Sezaby.

Likely market impact

Continued losses and revenue decline are concerning, but PRV grant for Sezaby is a positive. Promoter backing supports going concern.